Join
Live feed
·
INSIDERFilingvia Quantisnow
Decoy Therapeutics Inc. logo

Chief Financial Officer Rosenblum Mark J was granted 9,682 shares, increasing direct ownership by 576% to 11,363 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
DCOY· Decoy Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DCOY (Decoy Therapeutics Inc.) and more on Quantisnow.